Adlai Nortye Ltd. American Depositary Shares (ANL)
Stock · NASDAQ · Health Care
$11as of 10/16/2026
Price chart
Active signals
ANL Signal Track Record
How signals performed across all stocks →What ANL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 12 | +14.6% | 83% | October 5, 2026 |
| Bollinger Band BreakdownActive now | 10 | -6.7% | 30% | October 6, 2026 |
| Bollinger Band Breakout | 9 | +9.1% | 67% | September 22, 2026 |
| Any 20-session window (baseline) | -2.4% | 45% |
Computed by MarketWall from daily closing prices since July 17, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANL
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 109
- Website
- www.adlainortye.com/
Fundamentals
- 1-day range
- $10.93$12.04
- Market cap
- $1.01B
- P/E (trailing)
- —
- P/E (forward)
- -37.48
- EPS (trailing)
- $-0.41
- Dividend yield
- —
- Beta
- 1.40
- Avg. volume
- 210.9K
Forecasts
6 analyst ratings
Adlai Nortye Ltd. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ANLAdlai Nortye Ltd. American Depositary Shares$11.03▼ 8.77%Market cap $1.01BP/E —$0.879$17.25
- GERNGeron Corporation Common Stock$1.17▼ 4.88%Market cap $1.01BP/E —$1.04$2.01
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
- JANXJanux Therapeutics Inc. Common Stock$16.51▼ 4.68%Market cap $981.85MP/E —$12.12$35.34
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANL Adlai Nortye Ltd. American Depositary Shares | $1.01B | — | $11.03 | ▼ 8.77% | $0.879$17.25 |
| GERN Geron Corporation Common Stock | $1.01B | — | $1.17 | ▼ 4.88% | $1.04$2.01 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
| JANX Janux Therapeutics Inc. Common Stock | $981.85M | — | $16.51 | ▼ 4.68% | $12.12$35.34 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibodybenzinga · 10/15/2026
- Adlai Nortye Group: Only For The Risk-Tolerant After A Massive RallySeekingAlpha · 10/8/2026
- Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public RelationsYahoo · 9/30/2026
- 4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial ProgressYahoo · 9/15/2026
Insider Activity
Insider Actions →- Ji Ping · September 30, 2026 · Sale5.0K @ $16.03
- Ji Ping · September 29, 2026 · Sale214 @ $15.77
- Ji Ping · September 22, 2026 · Sale5.0K @ $16.63
- Ye Xiaofeng · August 26, 2026 · Sale5.7K @ $14.25
- Ye Xiaofeng · August 24, 2026 · Sale6.0K @ $13.98
- Ji Ping · June 10, 2026 · J136.7K
- LU YANG · May 13, 2026 · Sale10 @ $13.18
Institutional Ownership
March 31, 2026
- Total shares held
- 11.59M
- Total value held
- $79.49M
- Institutional holders
- 26
- Unknown3.21M
- Unknown2.90M
- Unknown1.27M
- Unknown877.8K
- Unknown681.8K
- Unknown538.5K
- Unknown538.5K
- Unknown414.9K
- Unknown209.3K
- Unknown164.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Adlai Nortye Partners with Lilly and Merck for AN4035 Trials
Adlai Nortye has entered clinical collaboration agreements with Eli Lilly and Merck KGaA to evaluate combining its AN4035 drug with Cetuximab. This partnership provides access to the ERBITUX antibody for upcoming trials. The stock has recently rallied significantly, moving from a 52-week low of $0.88 to a high of $17.25.
Adlai Nortye Partners with Lilly and Merck for AN4035 Trials. Adlai Nortye has entered clinical collaboration agreements with Eli Lilly and Merck KGaA to evaluate combining its AN4035 drug with Cetuximab. This partnership provides access to the ERBITUX antibody for upcoming trials. The stock has recently rallied significantly, moving from a 52-week low of $0.88 to a high of $17.25.